Prvi implantat cjepiva protiv klamidije koji je ikada bio ugrađen u divljeg koalu

A groundbreaking medical intervention took place in the Australian rainforests on May 19, 2026, when a young koala named Bamse became the first wild individual to receive a chlamydia vaccine implant. Developed by researchers at Queensland University of Technology (QUT) in collaboration with Currumbin Wildlife Hospital, the implant marks a pivotal step in the fight against a disease that has severely impacted koala populations across southeastern Queensland. Bamse, an 18-month-old female koala, was captured near Burleigh Heads and transported to Currumbin Wildlife Hospital for the procedure. Senior veterinarian Dr. Michael Pyne, alongside Dr. Freya Russell from QUT, sedated the animal and administered the first dose of the vaccine while inserting the biodegradable implant. Designed to release the second dose after 30 days, the implant eliminates the need for repeated captures, significantly reducing stress on the animals and streamlining the vaccination process. The koala was released back into its native bushland on the same day, equipped with a GPS collar for ongoing monitoring. Researchers plan to track Bamse’s health for at least six months to evaluate the efficacy of the implant. To date, five wild koalas from Burleigh have received the treatment, with Bamse and another koala undergoing a one-month checkup. Both have tested negative for chlamydia, indicating early signs of the method’s success. The initiative is part of a broader effort led by QUT and Currumbin Wildlife Hospital, supported by the World Wide Fund for Nature Australia. The project aims to bolster koala populations threatened by chlamydia, a bacterial infection that causes severe eye and urinary tract damage and can lead to blindness or death. Over 500 koalas have already been vaccinated at Currumbin Wildlife Hospital and the Moggill Koala Rehabilitation Center, contributing to a notable recovery in certain areas. Notably, the Elanora population on the Gold Coast saw a dramatic improvement following the implementation of the vaccine. In 2020, nearly 70% of koalas brought to Currumbin Wildlife Hospital were infected with chlamydia. After the introduction of the two-step vaccination protocol, initial injection followed by a booster, the rate of chlamydia-related admissions dropped by 75%. As a result, 41 joeys and 13 grand-joeys were born in the region, marking a resurgence in the local koala population. The success of the Elanora program laid the groundwork for the development of the implant. Traditionally, koalas required multiple captures for vaccinations, which was both logistically challenging and stressful for the animals. The new implant simplifies the process, allowing for a single capture and subsequent remote monitoring. It was initially tested on captive koalas, proving its effectiveness before being trialed in the wild. Recent findings from a study conducted by Dr. Lyndal Hulse of The University of Queensland further support the viability of widespread vaccination. The study analyzed data from over 1,100 koalas across Southeast Queensland and found substantial reductions in chlamydial disease and mortality among vaccinated individuals. Based on these results, Hulse recommended prioritizing regions such as Somerset, South Burnett, Redland City, Logan City, Western SEQ, and Moreton Bay for vaccination due to their high disease burdens. Logan City, for instance, reported alarming infection rates, with 58% of koalas testing positive for conjunctival chlamydia and 56% for urogenital tract infections. In contrast, areas like the Gold Coast and Brisbane have seen improved outcomes due to earlier vaccination efforts. Dr. Pyne emphasized the significance of the recent developments, stating that the implant represents a major breakthrough in koala conservation efforts.